
|Videos|June 12, 2015
Federal Compounding Law and Health-System Pharmacists
Chris Topoleski, director of federal regulatory affairs for ASHP discusses how the federal compounding law will affect health-system pharmacists.
Advertisement
Chris Topoleski, director of federal regulatory affairs for ASHP discusses how the federal compounding law will affect health-system pharmacists.
This video was taken at ASHP's Summer Meetings and Exposition in June 2015.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
3
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
4
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
5





















































































































































































































